Teen HPV Vaccine Rates Stall for First Time in a Decade
(MedPage Today) -- After rising steadily since 2013, new human papillomavirus (HPV) vaccinations in teens stalled for the first time in 10 years, a CDC report showed.
The proportion of 13- to 17-year-olds who received at least one dose of HPV... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 25, 2023 Category: Hematology Source Type: news
U.S. Kids ’ HPV Vaccination Rate Has Stalled
THURSDAY, Aug. 24, 2023 -- For the first time in a decade, the rate at which American adolescents received the human papillomavirus (HPV) vaccine has not increased, new data show.
Current guidelines from the U.S. Centers for Disease Control and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 24, 2023 Category: General Medicine Source Type: news
Nonpediatric Specialties Face Smaller Return Margins for HPV Vaccine Costs
MONDAY, July 31, 2023 -- For nonpediatric specialties, return margins for human papillomavirus (HPV) vaccine costs by private payers are small, according to a study published in the July/August issue of the Annals of Family Medicine.
Yenan Zhu,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2023 Category: Pharmaceuticals Source Type: news
Nepal Poised To Start HPV Vaccination To Prevent Cervical Cancer, Awaiting GAVI
As Dipak Subedi was organizing a vaccination programme against the human papillomavirus (HPV) in the city of Bharatpur in Chitwan district of southern Nepal he was getting phone calls from neighbouring districts asking if he had extra doses available — people were willing to travel for hours to get their girls vaccinated against HPV, which […] (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - July 31, 2023 Category: International Medicine & Public Health Authors: Marty Logan Tags: Asia-Pacific Gender Headlines Health TerraViva United Nations human papillomavirus (HPV) Source Type: news
What Are Treatments for Recurrent Respiratory Papillomatosis?
Discussion
Human papilloma virus (HPV) is a member of the Papillomaviridae virus family with over a 150 different subtypes. HPV can cause cervical, genital and respiratory tract papillomas. HPV is often benign but can cause anogenital, cervical and head and neck cancers.
Recurrent respiratory papillomatosis (RRP) is uncommon but can cause significant morbidity while awaiting the body’s immune system to respond. There is a juvenile and adult form, and the incidence varies between 2-4/100,000 in the pediatric population. The juvenile form frequently occurs between 3.6-6 years of age and in general the younger the patie...
Source: PediatricEducation.org - July 31, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news
A Shot in the Arm Can Prevent Cervical Cancer
Afshan Bhurgri, a cancer survivor, advises women to listen to their bodies and be aware of the symptoms of cervical cancer. Credit: Zofeen Ebrahim/IPSBy Zofeen EbrahimKARACHI, Jul 26 2023 (IPS) “Listen to your body, and if there is anything strange happening, do not ignore it,” is the advice of 57-year-old Afshan Bhurgri, a cancer survivor.
Eight years ago, she was diagnosed with cervical cancer at a time when she was “in a good place” in life. Her kids were grown up, and she had more time to herself. A fitness freak, the schoolteacher’s daily routine included going to the gym daily. “I joined a creative writin...
Source: IPS Inter Press Service - Health - July 26, 2023 Category: International Medicine & Public Health Authors: Zofeen Ebrahim Tags: Asia-Pacific Development & Aid Editors' Choice Featured Gender Headlines Health Human Rights Humanitarian Emergencies Sustainable Development Goals TerraViva United Nations Women's Health Education Cannot Wait (ECW) IPS UN Bureau Source Type: news
More CIN2+ Detection Seen With HPV Catch-Up Screening in Women Aged ≥65
TUESDAY, July 11, 2023 -- For women aged 65 to 69 years, catch-up human papillomavirus (HPV) screening is associated with higher cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2+) detection, according to a study published online July... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 11, 2023 Category: Pharmaceuticals Source Type: news
Liquid Biopsy May Help May Identify HPV-Associated Oropharyngeal Cancer
(MedPage Today) -- MONTREAL – Analysis of circulating human papillomavirus (HPV) tumor DNA and tumor DNA fragment (tumor tissue–modified viral ([TTMV])-HPV DNA using a commercially available blood test – a so-called liquid biopsy... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - July 10, 2023 Category: Surgery Source Type: news
Liquid Biopsy May Help Identify HPV-Associated Oropharyngeal Cancer
(MedPage Today) -- MONTREAL – Analysis of circulating human papillomavirus (HPV) tumor DNA and tumor DNA fragment (tumor tissue–modified viral ([TTMV])-HPV DNA using a commercially available blood test – a so-called liquid biopsy... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 10, 2023 Category: Hematology Source Type: news
Sample-to-Answer, Point-of-Care HPV DNA Test Feasible
TUESDAY, June 27, 2023 -- A sample-to-answer, point-of-care human papillomavirus (HPV) DNA test is feasible and can be performed by minimally trained personnel, according to a study published online June 21 in Science Translational Medicine.
Kathryn... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 27, 2023 Category: Pharmaceuticals Source Type: news
Roche awarded WHO prequalification for the cobas ® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries
Every year, over 600,000 women worldwideare diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 women who die from cervical cancer live in low- and lower-middle income countries (LMICs).1WHO prequalification enables LMICs to use thecobas® HPV test in their national cervical cancer elimination programs, increasing access to the patients who need it most.Establishing screening programs helps prevent and detect cervical cancer, which is especially important in areas with limited healthcare resources where patientsare often diag...
Source: Roche Investor Update - June 13, 2023 Category: Pharmaceuticals Source Type: news
Roche awarded WHO prequalification for the cobas ® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries
Every year, over 600,000 women worldwideare diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 women who die from cervical cancer live in low- and lower-middle income countries (LMICs).1WHO prequalification enables LMICs to use thecobas® HPV test in their national cervical cancer elimination programs, increasing access to the patients who need it most.Establishing screening programs helps prevent and detect cervical cancer, which is especially important in areas with limited healthcare resources where patientsare often diag...
Source: Roche Media News - June 13, 2023 Category: Pharmaceuticals Source Type: news
Harald zur Hausen, 87, Nobelist Who Found Cause of Cervical Cancer, Dies
When he proposed that the human papillomavirus caused cervical cancer, he was ridiculed. He persevered, and today a vaccine exists. (Source: NYT Health)
Source: NYT Health - June 9, 2023 Category: Consumer Health News Authors: Emily Anthes Tags: zur Hausen, Harald Deaths (Obituaries) Sexually Transmitted Diseases Cervical Cancer Human Papillomavirus (HPV) Vaccination and Immunization Nobel Prizes Research Source Type: news
